23andMe Investor Presentation Deck

We Are Redefining Healthcare. With Data. At Scale. Cumulative Genotyped Customers (in M, fiscal year ends March 31) 2.0 FY17A 4.4 FY18A 7.8 FY19A 10M+ Genetic Profiles Created Critical Mass 9.8 FY20A 11.3 FY21A 1. As of June 30, 2022. 2. As of March 31, 2022. Programs include collaborated, 100% owned and royalty interest targets. 12.8 FY22A 13.1 FY23Q1 Empowering Consumers 13.1M Genotyped Customers¹ Enabling Research & Services 425K 23andMe+ Subscribers² 4B+ Phenotypic Data Points² Developing Therapeutics 50+ Programs² Copyright © 2022 23and Me, Inc. 23andMe 11

View entire presentation